Details for New Drug Application (NDA): 213351
✉ Email this page to a colleague
The generic ingredient in CLOPIDOGREL BISULFATE is clopidogrel bisulfate. There are fifty-four drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the clopidogrel bisulfate profile page.
Summary for 213351
| Tradename: | CLOPIDOGREL BISULFATE |
| Applicant: | Polygen Pharms |
| Ingredient: | clopidogrel bisulfate |
| Patents: | 0 |
Pharmacology for NDA: 213351
| Mechanism of Action | Cytochrome P450 2C8 Inhibitors P2Y12 Receptor Antagonists |
| Physiological Effect | Decreased Platelet Aggregation |
Suppliers and Packaging for NDA: 213351
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CLOPIDOGREL BISULFATE | clopidogrel bisulfate | TABLET;ORAL | 213351 | ANDA | POLYGEN PHARMACEUTICALS INC. | 52605-082 | 52605-082-10 | 1000 TABLET in 1 BOTTLE, DISPENSING (52605-082-10) |
| CLOPIDOGREL BISULFATE | clopidogrel bisulfate | TABLET;ORAL | 213351 | ANDA | POLYGEN PHARMACEUTICALS INC. | 52605-082 | 52605-082-13 | 30 TABLET in 1 BOTTLE (52605-082-13) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 75MG BASE | ||||
| Approval Date: | Jul 17, 2020 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 300MG BASE | ||||
| Approval Date: | Jul 17, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
